Who are VKA-Based Regimen's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): standard intensity warfarin, Acenocoumarol VKA, Warfarin VKA.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/vka-based-regimen.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

VKA-Based Regimen — Competitive Intelligence Brief

VKA-Based Regimen (VKA-Based Regimen) competitive landscape: 3 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Vitamin K antagonist (VKA). Area: Cardiovascular.

phase 3 Vitamin K antagonist (VKA) Vitamin K epoxide reductase complex 1 (VKORC1) Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

VKA-Based Regimen (VKA-Based Regimen) — Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company. VKA-based regimens inhibit vitamin K-dependent clotting factors (II, VII, IX, X) to prevent thrombus formation.

Comparator set (3 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
VKA-Based Regimen TARGET	VKA-Based Regimen	Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company	phase 3	Vitamin K antagonist (VKA)	Vitamin K epoxide reductase complex 1 (VKORC1)
standard intensity warfarin	standard intensity warfarin	The First Affiliated Hospital with Nanjing Medical University	marketed	Vitamin K antagonist (VKA)	Vitamin K epoxide reductase complex 1 (VKORC1)
Acenocoumarol VKA	Acenocoumarol VKA	Sanofi	phase 3	Vitamin K antagonist (VKA)	Vitamin K epoxide reductase complex (VKORC1)
Warfarin VKA	Warfarin VKA	Sanofi	phase 3	Vitamin K antagonist (VKA); oral anticoagulant	Vitamin K epoxide reductase (VKORC1)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Vitamin K antagonist (VKA) class)

Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company · 1 drug in this class
Sanofi · 1 drug in this class
The First Affiliated Hospital with Nanjing Medical University · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). VKA-Based Regimen — Competitive Intelligence Brief. https://druglandscape.com/ci/vka-based-regimen. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab